2bind Expands Cell-Based Capabilities with New BSL2 Certified Laboratory
2bind GmbH, a leading CRO serving the global drug discovery and development sector, today announced the official commissioning of its newly established BSL2 cell culture laboratory.
2bind Launches Redesigned Website Aligned with Its “Pharma Services” Core Positioning
March 2026, Regensburg, Germany – 2bind GmbH, a leading contract research organization (CRO) serving the global drug discovery and development sector, today announced the official launch of its newly redesigned corporate website. Following the recent transition of its corporate identity from “Experts in Biophysics” to “Pharma Services,” this digital overhaul ensures that 2bind’s online presence fully reflects its expanded portfolio, modern assay ecosystem, and deep alignment with the biopharma market.
Evolution of a Trusted Partner: 2bind Transitions Corporate Identity from “Experts in Biophysics” to “Pharma Services”
2bind GmbH, a leading contract research organization (CRO) serving the global drug discovery and development sector, today announced a strategic evolution of its corporate identity. Reflecting its expanded portfolio and deep alignment with the life sciences industry, the company is transitioning its core positioning from “Experts in Biophysics” to “Pharma Services.”
2bind Announces New Co-CEO Leadership Team
2bind GmbH, a leading contract research organization (CRO) specializing in biophysical analysis for drug discovery and antibody development, today announced a transition in its executive leadership. Dr. Thomas Schubert, Co-CEO, has decided to step down from his role, effective October 31, 2024, to pursue other opportunities and dedicate more time to his family.
2bind Opens New Headquarters
2bind GmbH Opens New Headquarters to as a Result of Quality Work and Continued Growth
Dr. Cosimo Kropp joins executive team as CBO
2bind GmbH Elevates Dr. Cosimo Kropp to Chief Business Officer
Launch of Antibody Unit with Dr. Vera Molkenthin as Director
2bind GmbH Launches Antibody Unit with Appointment of Dr. Vera Molkenthin as Director
Dr. Cosimo Kropp Hired as New Director Business Development
2bind GmbH Strengthens Business Development with Appointment of Dr. Cosimo Kropp
Regensburg Biotech Hub Combats COVID-19 with High-Tech Research Project
A collaborative research project based in Regensburg is leveraging cutting-edge technology and expertise to develop a novel drug against COVID-19. The project unites 2bind GmbH, a leading biophysical analysis company located in BioPark Regensburg, with researchers from the University of Regensburg and the Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM).
2bind Supports Novel Concept Towards Prophylactic HIV-Vaccine
The federally funded interdisciplinary research project “HIVacToGC” was launched to investigate new approaches to the prevention and treatment of HIV infections.